Nanobased Platforms for Diagnosis and Treatment of Covid-19: From Benchtop to Bedside Publisher Pubmed

Summary: Can nanotech outsmart coronaviruses like SARS-CoV-2? A review suggests nanobiosensors enable early detection, while nanoplatforms offer antiviral tools against mutations—potentially transforming diagnostics and vaccines for global outbreaks. #Nanomedicine #Coronavirus

Bidram E¹ ; Esmaeili Y¹ ; Amini A^{2, 3} ; Sartorius R⁴ ; Tay FR⁵ ; Shariati L^{6, 7} ; Makvandi P⁸
Source: ACS Biomaterials Science and Engineering Published:2021

Abstract

Human respiratory viral infections are the leading cause of morbidity and mortality around the world. Among the various respiratory viruses, coronaviruses (e.g., SARS-CoV-2) have created the greatest challenge and most frightening health threat worldwide. Human coronaviruses typically infect the upper respiratory tract, causing illnesses that range from common cold-like symptoms to severe acute respiratory infections. Several promising vaccine formulations have become available since the beginning of 2021. Nevertheless, achievement of herd immunity is still far from being realized. Social distancing remains the only effective measure against SARS-CoV-2 infection. Nanobiotechnology enables the design of nanobiosensors. These nanomedical diagnostic devices have opened new vistas for early detection of viral infections. The present review outlines recent research on the effectiveness of nanoplatforms as diagnostic and antiviral tools against coronaviruses. The biological properties of coronavirus and infected host organs are discussed. The challenges and limitations encountered in combating SARS-CoV-2 are highlighted. Potential nanodevices such as nanosensors, nanobased vaccines, and smart nanomedicines are subsequently presented for combating current and future mutated versions of coronaviruses. © 2021 American Chemical Society. All rights reserved.